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number of scenarios where the EVPI curve takes a different form compared to the 
one illustrated in the typical ‘textbook’ example. For example, when the majority of 
the plotted outcomes are spread over the northern quadrants the traditional EVPI 
peak is absent, and this could be explained by the fact that the reduction in decision 
uncertainty does not outweigh the increased value of opportunity loss. Further, plots 
spread over the eastern quadrants present a maximum EVPI at zero λ which then 
gradually decreases. This study may inform the interpretation of EVPI curves, and 
add value to the analysis of the value of additional research.
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Objectives: Real-world patients do not exhibit the level of medication adherence 
seen in clinical trials. Hence, the effectiveness of medications in routine practice 
may differ. It is important to understand the manifestations of suboptimal medi-
cation adherence in a population to assess the potential of adherence-improving 
interventions and the real-world value of medications. The objective of our study 
was to compare the clinical outcomes of an adherence naïve framework versus 
a dynamic adherence framework using the case of statins for primary preven-
tion of cardiovascular disease versus no statin use. MethOds: Statin adherence 
was categorized as PDC≤ .20, .20< PDC< .80 and PDC≥ .80 based on a longitudinal 
epidemiological cohort study of US medical and pharmacy claims. Yearly adher-
ence transitions were incorporated into a Markov microsimulation using Treeage 
software. Tracker variables were used to store adherence transitions which were 
then used to adjust probabilities of cardiovascular events (MI, stroke, acute angina) 
over the patient’s lifetime. Statin effectiveness was adjusted between 0% and 
100% of trial-based risk reduction. A total of 10,000 microsimulations were used 
to estimate incremental effectiveness as CV events avoided and quality-adjusted 
life-years (QALYs). Results: In the 10,000-patient statin user cohort simulated 
by the adherence-naïve model, it was estimated that statin use resulted in 1,162 
CV events avoided and 0.39 QALYs gained over a lifetime horizon. The dynamic 
adherence model estimated that 42% of patients exhibited highest adherence, 40% 
exhibited intermediate adherence and 18% exhibited low adherence. This model 
simulated that overall, statin use resulted in 366 events were avoided and 0.18 QALYs 
gained. cOnclusiOns: A Markov microsimulation used to simulate changes in 
patients’ medication adherence over time reveals differential risk reduction and 
effectiveness in terms of CV events and QALYs gained. The framework presented 
here is useful for comparing drugs in which optimal effectiveness and costs may 
be similar, but differential adherence may affect outcomes.
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Objectives: In recent years the financer in Hungary (NHIFA) has established a 
detailed and stabile patient turnover database, which reflects time dependent 
changes. Meanwhile, statistical methods of longitudinal data revealing causal 
relationship have been becoming widespread. By these new methods, analyses 
similar to assessment of randomized clinical trials have become available. In 
our research we studied the causal effects of the strategy of treatment, espe-
cially the frequency of retreatment of responder patients on features of status, 
events and costs of patients diagnosed Hepatitis C. MethOds: Causal infer-
ence on longitudinal (e.g. patient path) data is possible using the methods of 
Robins (1999). It makes therapy history exogenous, i.e. independent of the actual 
status of the patient via dynamical, time dependent reweighting of individual 
patient paths. Consequently, patient paths can be analyzed similarly to cohort 
data assessment of randomized clinical trials. The method can be used to con-
firm the results of RCTs. It can substitute RCTs, too, e.g. if RCTs are ethically 
impossible. Results: We obtained by applying Robins’ method that repeated 
combination therapies decreased the risk of liver related complications and the 
development of hepatocellular carcinoma. The method applied to cost analysis 
revealed that despite repeated therapies the costs of newly developed cirrhosis 
and tumor are higher than the corresponding costs of patients with sustained 
viral response. cOnclusiOns: Robins’method is appropriate for measuring the 
causal effects of certain factors of care on patient pathways, especially if patient 
turnover data are supplemented with physiologic, diagnostic and lab information 
found in clinical registers.
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Objectives: Decision analytic modellers use numerous types of evidence for 
populating model parameters. Detailed methodological advice on which type of 
data is to be used for what type of model parameter is required. We aim at review-
ing existing HTA manuals and health economic (modelling) guidelines in order to 
gain advice on appropriate evidence sources for populating models. MethOds: 
We identified manuals and guidelines via the International Network of Agencies 
for Health Technology Assessment (INAHTA) and by hand search. We included 
documents from Europe, the USA, Canada, Australia and New Zealand as well as 
transnational guidelines written in English or German. We systematically sum-
to characterize the underlying disease progression parameters and strengthen 
these assessments.
PRM90
oveRvieW of health econoMic Models in tyPe 2 diabetes Mellitus 
(t2dM); a systeMatic liteRatuRe RevieW
Charokopou M.1, Sabater F.J.2, Townsend R.3, Roudaut M.2, Verheggen B.G.1
1Pharmerit International, Rotterdam, The Netherlands, 2Bristol-Myers Squibb, Rueil-Malmaison, 
France, 3AstraZeneca, Brussels, Belgium
Objectives: To identify and compare economic models developed to evaluate the 
cost-effectiveness of treatments for type 2 diabetes mellitus (T2DM), and their use 
in health care decision-making. MethOds: This research updates two previously 
published systematic reviews. The current systematic literature review was per-
formed according to a pre-defined search strategy and review criteria in six com-
monly used databases from September 2008 to January 2013. In addition, websites 
of Health Technology Assessment (HTA) organizations across nine countries and 
major disease conferences’ proceedings were also reviewed. For each identified 
model, key information was extracted and assessed. Results: Overall, 2262 cita-
tions were identified; 122 full text publications, 169 conference proceedings and 106 
HTA reports met the pre-defined inclusion criteria. Among these, 27 models were 
identified; 6 from full text publications, 18 models from conference proceedings, and 
3 models from HTA reports. Most of the included models applied a similar model 
structure, either using Markov-modelling or micro-simulation techniques, and were 
based on similar key data sources. A key challenge of T2DM economic modelling is to 
appropriately predict the long-term progression of relevant risk factors and translate 
these into clinical and economical consequences of diabetes-related complications. 
In line with previous findings, the UKPDS risk equations were most commonly used 
for the above purposes in the newly identified models. Among published studies and 
HTA submissions, T2DM economic models that are widely published and accepted 
by HTAs include CARDIFF and CORE. cOnclusiOns: The most commonly employed 
models in HTA submissions, namely CARDIFF and CORE, have similar techniques 
to forecast future costs and health outcomes. Hence, the focus for decision makers 
should be to consider the appropriateness of the critical assumptions regarding 
data inputs that impact the results.
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Objectives: To estimate the relative efficacy of aclidinium bromide 400 µg 
BID (AB400), to tiotropium bromide 18 µg QD (TIO18) by means of lung function 
in patients with COPD, within the first 24 weeks of treatment and illustrate the 
repeated measures network meta-analysis (NMA) models. MethOds: A system-
atic literature search using a predefined strategy in MEDLINE, EMBASE and the 
Cochrane Library identified 16 unique placebo-controlled RCTs reporting FEV1 
trough: TIO18 (n= 13) and AB400 (n= 3). The development of trough FEV1over time 
for AB400, TIO18 and placebo (PLA) was modeled with fractional polynomials, and 
the difference between the parameters of these polynomials within a trial were 
synthesized across studies with a Bayesian NMA. This type of NMA allows for the 
simultaneous analysis of outcomes at multiple time points. The within-trial cor-
relation was not available from the publications of the included studies, and as 
such a sensitivity analyses was performed assuming different values for the cor-
relation. Results: Given the fractional polynomial parameters obtained with the 
NMA model, the corresponding treatment effects over time for AB400 vs TIO18, 
AB400 vs PLA and TIO vs PLA were estimated. The model with t-0.5and log(t) had 
the best fit according to the deviance information criterion (DIC). These polynomi-
als and within study correlation were used for the modeling of the outcomes over 
time. AB400 is equally efficacious compared to TIO18 during the first 24 weeks, as 
the 95% CrI of the difference in CFB between the treatments includes zero while 
the mean is < 15mL. Furthermore, the probability that each treatment was best was 
calculated as a function of time. cOnclusiOns: This analysis demonstrates the 
use of the proposed NMA models and suggests that maintenance treatment with 
AB400 results in comparable improvements in lung function, as TIO18 in COPD 
patients over a 24 weeks period.
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When making decisions about the allocation of scarce health-care resources it’s 
not only important to consider the estimated cost-effectiveness (CE) with current 
evidence, but also the value of additional research. Expected value of perfect infor-
mation (EVPI) is the amount a decision maker should be willing to pay to eliminate 
uncertainty surrounding the decision about which option is optimal for different 
levels of the CE threshold (λ ). Although EVPI analysis is being requested increasingly 
by reimbursement agencies there is still limited literature on the interpretation 
of EVPI curves. The typical ‘textbook’ example represents just one of the possi-
ble shapes that the curve can take. Objectives: To explore and explain different 
shapes of EVPI curves based on the position of alternative treatment choices on 
the incremental cost-effectiveness plane. MethOds: A hypothetical probabilistic 
decision model was developed in which two interventions were compared. Key 
input parameters were varied to force the model outcomes into different quad-
rants on the incremental CE plane. The population EVPI, based on a hypothetical 
number of future patients and the estimated lifetime of the new intervention, was 
plotted. Results And cOnclusiOns: The result of this study demonstrates a 
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escalation thresholds influences predicted costs and quality adjusted life expec-
tancy (QALE) in T2DM economic evaluations. MethOds: This study used the IMS 
Core Diabetes Model (CDM), a validated and established diabetes model, to evaluate 
the cost effectiveness of metformin+ sulphonylurea (M+S) compared to metformin 
+ DPP-4 (M+D). Baseline HbA1c was set to 8.0% (non-sampled scenario) with stand-
ard error of 0.8 (sampled scenario). Efficacy data for dual therapy was sourced from a 
published systematic review; HbA1c and BMI changes of -0.8% and 0.199kg/m2 (M+D) 
and -0.79% and 0.707kg/m2 (M+S) respectively were applied. Insulin rescue therapy 
was applied to both arms at HbA1c thresholds of 6.5%, 7.0% 7.5%. The model was 
run over a lifetime and costs (US$) and benefits were discounted at 3.5%. Results: 
Total incremental costs were $7,667, $9,571 and $11,644 for M+D versus M+S using 
sampled baseline HbA1c for therapy escalation thresholds of 6.5%, 7.0% 7.5% respec-
tively; and were $5,258, $2311 and $206 lower using non-sampled values, respec-
tively. A similar pattern was observed for QALE, in which incremental QALE gains 
were 85%, 42% and 1% lower with non-sampled compared to sampled baseline 
HbA1c for escalation thresholds of 6.5%, 7.0% 7.5% respectively. cOnclusiOns: 
The importance of probabilistic analysis within cost effectiveness models extends 
beyond quantifying the effects of parameter uncertainty. When treatment decision 
rules are dependent on patient attributes that are subject to variability (such as 
HbA1c) then failing to accommodate this within the model can significantly bias 
predicted costs and QALE.
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Objectives: This study aims at reviewing structural differences in Markov Models 
comparing different treatment strategies for Non-Metastatic Prostate Cancer related 
to scope, time-horizon, perspective, assumptions and the selection of parameters 
for the model. MethOds: There is an abundant literature on Prostate Cancer. There 
are however few well performed RCT’s comparing different options for management 
for NMPCa.[1] Due to the lack of conclusive clinical evidence on the best treatment 
for localised prostate there has been a considerable interest in the modelling of 
prostate cancer in decision analytic models and economic evaluation.[2] The lit-
erature review in this paper focuses on the limited number of papers on economic 
evaluation related to the condition. In addition there are several articles presenting 
Markov Models. The evaluation was based on selected items from “Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS)”. Results: In NMPCa 
there are Markov models ranging from two to five health states [9]. The choice of 
model originates from the underlying assumptions, the aim/scope of the study or 
the availability of data to feed into the model. The insufficient clinical evidence 
and few preference based studies of health state values where the most influen-
tial elements in structuring the models Little attention is paid to the structural 
differences in the analysis and the discussions in the available papers. Structural 
uncertainty is viewed as external to the model and difficult to evaluate unless the 
structural choices are made transparent.[10]. cOnclusiOns: Models in NMPCa 
differ in complexity and structure. The ability to evaluate the use of different models 
is highly dependent on transparency in the different building blocks. The CHEERS 
framework provided a useful tool in the evaluation input factors and the different 
Markov Model structures,
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Objectives: Particularly in the context of HTA evaluations where both post-mar-
keting and pre-marketing data may be considered, the evidence to be synthesized 
can be sparse, partial and heterogeneous for safety outcomes. The Bayesian option 
has increasingly appeared as an unrivalled option for such challenging evidence 
synthesis cases but implementation in practice may be questioned. This work aims 
at determining how Bayesian meta-analysis or mixed treatment comparison of 
safety data can be optimized especially regarding the choice of prior distributions 
and model parameterization. MethOds: Based on the latest developments from 
the DIA working group on Bayesian methods for safety data applied to specific 
real-world cases of both direct meta-analysis and mixed treatment comparisons 
(MTC), different model parameterizations and different forms of informative and 
non-informative prior distributions are tested, with various weights allocated to the 
clinical data vs. the observational information. Results: As opposed to the NICE 
parameterization of network meta-analysis, the 2-way predictor parameterization 
of MTC as proposed by the DIA working group provides more robust analysis based 
on non-informative priors. In the case of informative prior results, the most robust 
option was seen for equal total weight of clinical vs. observational data. Results 
of all meta-analyses appeared to be consistent across different model and prior 
specifications, even with low number of studies (< 10). cOnclusiOns: Bayesian evi-
dence synthesis can leverage all available information in a robust manner for both 
direct and indirect comparisons, with fair quantification of uncertainty. Specific 
guidance on MTC model parameterization for safety data could complement the 
current NICE guidelines.
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Objectives: To analyse the half-cycle correction and its effect on the final results 
of Markov models. MethOds: In our analysis we focus on the half-cycle correction, 
which is a method used to deal with the inaccuracy caused by inadequate cycle 
marised recommendations on appropriate evidence sources for different model 
parameters in a narrative manner. Additionally, information on advantages and 
disadvantages of sources, on evidence identification methods and on data quality 
issues was extracted. Results: Twenty-eight documents fulfilled our inclusion 
criteria. We identified a large variety of evidence sources for informing model 
parameters on clinical effect size, natural history of disease, resource use, unit 
costs and health state utility values. They comprise research and non-research 
based sources. The documents do not provide structured advice on the hierarchy 
of evidence and on the limitations of evidence sources. The information is pre-
sented fragmentarily and is not tailored to specific model types. cOnclusiOns: 
The usability of guidelines and manuals for modelling could be improved by 
addressing the issue of appropriate evidence sources in a more structured and 
comprehensive format.
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Objectives: When the appropriate time horizon exceeds the evidence time 
horizon in a cost-effectiveness decision model, numerous uncertainties arise. 
One potential source of uncertainty is that of a possible future event that may 
affect one or more model parameters, e.g. a price shock or the emergence of 
a new comparator. These uncertain future events (UFEs) are rarely accounted 
for in health technology assessment and there is a dearth of guidance regard-
ing how they should be modelled. The objective of this study is to describe the 
circumstances under which UFEs could meaningfully impact cost-effectiveness 
estimates and to explore and demonstrate appropriate modelling techniques 
using a motivating example. MethOds: Drawing on examples from HTA and 
other relevant literature, a framework is proposed to outline: when to take 
explicit account of uncertain future events for the purposes of reimbursement 
decisions, how different future events may affect value-of-information analysis 
and what modelling methods are likely to be useful when incorporating UFEs. 
Taking the example of a decision model seeking to estimate the cost-effective-
ness of an early interventional strategy for patients with non-ST-elevation acute 
coronary syndrome, a future price change is simulated and the framework is 
applied. Results: UFEs are shown to impact ‘accept or reject’ reimbursement 
decisions only in very specific circumstances where there is the potential to 
incur irrecoverable costs, whereas their role in value-of-information analysis is 
invariable. The applied example shows that the reimbursement recommenda-
tion for future populations may change with the occurrence of the future event 
and that there is value in reducing the uncertainty regarding the nature of the 
future event. cOnclusiOns: UFEs will only impact expected costs-effectiveness 
sunder specific and rare circumstances. When it is appropriate to include a future 
event in a decision model, the uncertainty surrounding its likelihood, timing and 
magnitude should also be quantified.
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Objectives: Modelling for cost-effectiveness studies often relies upon the use of 
spreadsheets. However, research has shown that approximately 90% of spread-
sheets contain technical errors. Furthermore, cost-effectiveness models rely on 
accurate transcription between many data sources, which increases the risk of 
errors further. The objective of this analysis was to ascertain the incidence of 
reported technical errors in cost-effectiveness models submitted to NICE as part of 
the Single Technology Assessment (STA) programme, which are subject to rigorous 
assessment by Evidence Review Groups (ERGs). MethOds: NICE guidance docu-
ments were searched for a wide range of technical error types using the HTAinsite 
database. Reports were included if the ERG had identified technical errors in the 
manufacturer’s submission and this had been noted at committee level. Included 
appraisals were analysed to identify categories of errors identified. Results: Of 
the 102 completed STA Guidance documents searched, 39 appraisals met the inclu-
sion criteria of the study, representing a technical error incidence of 38.2% (95% CI: 
28.8 – 48.4%). Within these studies, 47 errors were identified in the following areas: 
computation (47%), logic (17%), transcription (13%) and data handling (9%). Error 
causes could not be determined in 15% of cases. The magnitude of effect caused by 
technical errors was difficult to determine, because corrected models often include 
additional changes to parameters or model structure. cOnclusiOns: The inci-
dence of technical errors identified in the STA programme was lower than has 
previously been observed in studies of spreadsheet validity although this analysis 
assumes that ERG groups will identify all technical errors. The true incidence of 
errors may be higher than reported by this analysis. Use of best-practice methods 
and increased awareness of the causes and identification of technical errors may 
help to reduce their pervasiveness.
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Objectives: Due to the progressive nature of type 2 diabetes mellitus (T2DM), 
patients inevitably require therapy escalation or intensification. In health economic 
analyses, sampling input parameters is routinely undertaken for probabilistic analy-
sis but non-sampled analysis (mean values) is still commonplace. The objective of 
this study was to assess how sampling baseline HbA1c in combination with therapy 
